Wedbush Analysts Increase Earnings Estimates for NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Wedbush increased their Q2 2025 earnings estimates for shares of Neurocrine Biosciences in a report released on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.12 per share for the quarter, up from their previous estimate of $1.11. Wedbush has a “Outperform” rating on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q3 2025 earnings at $1.34 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $3.92 EPS, FY2026 earnings at $5.77 EPS, FY2027 earnings at $8.90 EPS, FY2028 earnings at $10.49 EPS and FY2029 earnings at $13.78 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). The company had revenue of $572.60 million during the quarter, compared to analysts’ expectations of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Neurocrine Biosciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.20 earnings per share.

Several other equities research analysts have also commented on the company. Royal Bank of Canada upped their price target on Neurocrine Biosciences from $137.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 6th. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 20th. JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Wednesday, March 26th. HC Wainwright dropped their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating for the company in a research report on Tuesday, April 22nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $150.00 price target (down from $185.00) on shares of Neurocrine Biosciences in a research report on Friday, March 7th. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $162.00.

Neurocrine Biosciences Stock Down 1.5 %

NBIX stock opened at $115.71 on Friday. The company has a market cap of $11.45 billion, a price-to-earnings ratio of 35.17, a PEG ratio of 0.77 and a beta of 0.26. The business has a fifty day simple moving average of $106.23 and a 200-day simple moving average of $121.85. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $157.98.

Neurocrine Biosciences declared that its Board of Directors has initiated a share buyback program on Friday, February 21st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the firm’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $4,131,508.20. This trade represents a 44.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin Charles Gorman sold 5,844 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the sale, the director now directly owns 521,618 shares of the company’s stock, valued at $60,867,604.42. The trade was a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,907 shares of company stock valued at $4,935,982. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Golden State Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at approximately $25,000. Huntington National Bank increased its stake in Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group raised its holdings in shares of Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 115 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $34,000. Finally, GeoWealth Management LLC boosted its holdings in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after buying an additional 102 shares during the period. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.